Neoplasms, Cystic, Mucinous, and Serous
6
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Low Rectal Cancer Study (MERCURY II)
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor
Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms